High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement
Status:
Unknown status
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This prospective trial will assess the activity and feasibility of a new high-dose
methotrexate-based high-dose sequential chemotherapy combination in patients with B-cell
lymphomas and CNS involvement at diagnosis or relapse. Selected drugs, with a well-documented
anti-lymphoma activity, will be administered at high doses to increase blood-brain barrier
penetration and CNS bioavailability as well as to reduce potential cross-resistance.